Heart failure & cardiomyopathies
124Iodine Evuzamitide Positron Emission Tomography in Patients With Established or Suspected Cardiac Amyloidosis
Authors' conclusion
124I-evuzamitide PET provides excellent diagnostic accuracy in patients known or suspected to have CA and might provide a single upstream assessment for the presence or absence of CA.
Study context
- Population
- Consecutive patients with known or suspected cardiac amyloidosis (CA)Positron emission tomography (PET)/MRI 123, PET/CT 3
- Participants
- 126 patients
- Comparison
- 124I-evuzamitide PET in patients with vs without CA
- CAn = 87
- Outcome
- Diagnostic performance and safety of 124I-evuzamitide PET/MRI (positive scan: LV myocardial uptake > blood pool, visual read by 3 experts)
Methodological detailsopen-label, prospective, consecutive patients
- Open-label
- Prospective
- Consecutive patients
Performance
As reported in the abstract
Visual scan read for CA
| Test or model | Sensitivity | Specificity |
|---|---|---|
| CA | 100% | Not reported in the abstract |
| No CA | Not reported in the abstract | 100% |
Sensitivity
CA100%
No CANot reported in the abstract
Specificity
CANot reported in the abstract
No CA100%
- Inter-reader agreement (Fleiss's kappa); disagreement on 5 patients, none with CA
- 0.94
Further findings
Mean
| Outcome | CA | No CA | P value |
|---|---|---|---|
| LV/blood pool standardized uptake value ratio | 1.89 (SD 0.29) | 0.91 (SD 0.15) | P < 0.001 |
Safety
Tracer-related adverse events
- Well tolerated, without significant tracer-related adverse events
Original publication
124Iodine Evuzamitide Positron Emission Tomography in Patients With Established or Suspected Cardiac Amyloidosis. JACC Cardiovasc Imaging. Published 30 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it